摘要
类风湿关节炎(RA)是一种常见的慢性炎症性自身免疫病,表现为骨和软骨的进行性破坏,严重者会造成全身多器官功能损伤。目前,RA的发病机制尚不完全清楚,可能与免疫、遗传、细胞因子和环境等因素有关。二妙散作为中医治疗湿热痹症的经典方剂,由苍术、黄柏等比配伍构成,对RA有明显治疗作用。为提升中医药治疗的认同性和科学性,现将二妙散配伍组方理论及二妙散治疗RA的药理实验研究做一综述,从动物水平和细胞水平进行归纳总结,旨在为临床应用二妙散治疗RA提供更多的理论依据。
Rheumatoid arthritis(RA)is a common chronic inflammatory autoimmune disease,which is characterized by the progressive destruction of bone and cartilage.In severe cases,it can cause systemic multiple organ dysfunction.At present,the pathogenesis of RA is not completely clear,which may be related to immune,genetic,cytokines and environmental factors.Ermiao powder,as a classic Chinese medicine prescription for treating damp-heat arthralgia,is composed of atractylodis and phellodendron in equal ratio,and has obvious therapeutic efficacy on RA.In order to enhance the identity and scientificity of traditional Chinese medicine treatment,the compatibility theory of Ermiao powder and the pharmacological experimental research of Ermiao powder in the treatment of RA is summarized in this paper.It is summarized from animal level and cell level,so as to provide more theoretical basis for clinical application of Ermiao powder in the treatment of RA.
作者
李玉彤
刘静淑
冯玉明
李振
LI Yutong;LIU Jingshu;FENG Yuming;LI Zhen(College of Basic Medical Sciences,Shanxi University of Chinese Medicine,Shanxi,Jinzhong 030619,China;Department of Forensic Identification,Hebei Eye Hospital,Hebei,Xingtai 054000,China)
出处
《中国医药科学》
2022年第21期52-55,67,共5页
China Medicine And Pharmacy
基金
国家自然科学基金项目(81904034)
山西中医药大学博士科研启动基金项目(2020BK02)
山西中医药大学2021年科技创新能力培育计划“青年科学家培育专题”项目(2021PY-QN-04)
基于炎性反应的重大疾病创新药物山西省重点实验室2021年度开放课题(2021sxcxyw01)。
关键词
类风湿关节炎
二妙散
组方理论
药理实验研究
Rheumatoid arthritis
Ermiao powder
Compatibility theory
Pharmacological experimental research